Who is sponsoring NCT05142709?

NCT05142709 is sponsored by Fudan University.

What drugs are being tested in NCT05142709?

Interventions in NCT05142709: Anti-PD-1 Immune Checkpoint Inhibitors.

What condition does NCT05142709 study?

NCT05142709 studies Metastatic Esophageal Squamous Cell Carcinoma.

Is NCT05142709 still recruiting?

NCT05142709 is currently completed. Last updated 5 February 2026.

Last reviewed 2026-02-05 · How we verify

NCT05142709

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Real-world Experience of ICIs Plus Chemotherapy for Advanced ESCC.

Completed Last updated 5 February 2026

What this trial tests

trial testing Anti-PD-1 Immune Checkpoint Inhibitors in Metastatic Esophageal Squamous Cell Carcinoma in 1,197 participants. Completed in 31 December 2025.

Timeline

31 October 2021

Primary endpoint
30 September 2023

31 December 2025

Quick facts

Lead sponsor	Fudan University
Status	Completed
Study type	OBSERVATIONAL
Enrollment	1,197
Start date	31 October 2021
Primary completion	30 September 2023
Estimated completion	31 December 2025
Sites	23 locations across China

Drugs / interventions tested

Anti-PD-1 Immune Checkpoint Inhibitors — full drug profile →

Conditions studied

Metastatic Esophageal Squamous Cell Carcinoma — all drugs for Metastatic Esophageal Squamous Cell Carcinoma →

Sponsor

Fudan University

Who can join

18 and older, any sex, with Metastatic Esophageal Squamous Cell Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a multi-center, non-interventional study. Clinicopathologic, treatment , outcome and efficacy data will be collected from medical records in metastatic esophageal squamous cell carcinoma (ESCC) patients.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Effectiveness and safety of first-line pembrolizumab plus chemotherapy in patients with advanced/recurrent or metastatic esophageal squamous cell carcinoma in China: a real-world multicenter study.
Lin Y, Shen W, Ye J, Luo H, et al · · 2024 · cited 1× · PMID 39563718 · DOI 10.1177/17588359241297092
The role of thoracic radiotherapy in the setting of immunotherapy in polymetastatic esophageal squamous cell carcinoma: a multi-center cohort study.
Liu Q, Chen J, Shen W, Ye J, et al · · 2026 · PMID 41696558 · DOI 10.1177/17588359261419635
Immune checkpoint blockade in cancer: current insights and future horizons.
Saman H, Makni-Maalej K, El-Ella DMA, Al-Tamimi MY, et al · · 2026 · PMID 41483376 · DOI 10.1007/s12672-025-04361-7
Comparative analysis of immunochemotherapy with versus without radiation therapy for stage IVB esophageal squamous cell carcinoma confined to non-regional nodal metastases: a multicenter propensity score matching study.
Liu Q, Chen J, Xu Y, Shen W, et al · · 2025 · PMID 41251846 · DOI 10.1007/s00262-025-04228-4

Verify or expand the search:

Other recruiting trials for Metastatic Esophageal Squamous Cell Carcinoma

Currently open trials in the same condition.

NCT06265285 — Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access an · Phase 2 · recruiting
NCT06138028 — Sintilimab and Chemotherapy Sequential Radiotherapy in Advanced Esophageal Cancer · Phase 2, PHASE3 · recruiting
NCT04949256 — Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Me · Phase 3 · active not recruiting
NCT04460937 — Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal an · Phase 1 · active not recruiting
NCT01142388 — Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or · Phase 2 · active not recruiting

Other Fudan University trials

Trials by the same sponsor.

NCT06196671 — Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer · Phase 2 · not yet recruiting
NCT07423611 — ctDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer · Phase 2 · not yet recruiting
NCT07410559 — Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Bre · Phase 2 · not yet recruiting
NCT07490119 — Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer · Phase 2 · not yet recruiting
NCT07497919 — A Study of Becotatug Vedotin Combined With Pucotenlimab in the Treatment of EGFR-Positive Advanced Penile Cancer · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05142709 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fudan University
Last refreshed: 5 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05142709.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing